Jubilant Generics Roorkee facility determined as official action indicated
Advertisement
Noida: Jubilant Pharmova Limited's wholly owned subsidiary Jubilant Pharma Limited, today announced that its subsidiary Jubilant Generics Limited (JGL) has received a communication from the US Food and Drug Administration (USFDA) through which the latter intimated that pursuant to its July-Aug 2022 audit of JGL's Solid Dosage Manufacturing facility at Roorkee it has determined inspection classification of the facility as "official action indicated".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.